The Time Course Changes in Bone Metabolic Markers after Administering the Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand Antibody and Drug Compliance among Patients with Osteoporosis.

CONCLUSIONS: Our study suggests that anti-RANKL antibody treatment suppresses bone resorption and maintains bone formation. PMID: 26097648 [PubMed]
Source: Asian Spine Journal - Category: Orthopaedics Tags: Asian Spine J Source Type: research